Drugs and patents in ATC class C10B - LIPID MODIFYING AGENTS, COMBINATIONS

Last updated: June 9, 2026

ATC C10B is dominated by fixed-dose and co-medication strategies that combine lipid-modifying mechanisms, especially statin-based combinations, ezetimibe, and newer add-ons targeting pathways that sit upstream and downstream of LDL production and clearance. The patent landscape is shaped by two layers: (1) active-ingredient composition and (2) formulation or dosage-form IP that can extend exclusivity beyond the initial compound grants. For market entry planning, the key risk is not only patent expiry but also method-of-use claims (dose titration, regimen sequencing, patient- or outcome-based uses) and formulation patents (bioavailability, FDC stability, and specific dose strengths).

What patents protect ATC C10B lipid-modifying combinations (statin/ezetimibe and beyond)?

Short answer: Protection typically clusters around the specific combination components, fixed-dose compositions, and dosing regimens. In the US, the Orange Book typically lists patents tied to the branded fixed-dose product and key method-of-use or formulation components; outside the US, national phase and SPCs (where applicable) extend exclusivity.

Which combination types drive C10B protection density?

Common C10B market segments and the typical IP categories behind them:

Statin + ezetimibe fixed-dose combinations
- Composition-of-matter and salt/form claims on each API plus combination compositions
- Formulation patents covering tablets, film coatings, particle size control, dissolution profiles, and stability
- Method-of-use patents tied to LDL-C reduction thresholds, specific target populations, and titration strategies
Statin + other lipid-modifying add-ons (non-ezetimibe)
- Combination-specific claims are common when the combination is fixed-dose
- For non-fixed co-administered products, method-of-use and regimen patents matter more than formulation claims
PCSK9 inhibitor and LDL-clearance strategy add-ons
- Outside C10B’s fixed-dose focus, biologic combos can still map to lipid-modifying combinations in practice
- IP centers on antibodies, epitopes, manufacturing, and method-of-use; formulation patents are less relevant than for oral products

How many patents typically cover a single C10B fixed-dose launch?

A branded C10B fixed-dose product often has:

Multiple composition and salt polymorph patents (sometimes per API)
Multiple formulation/dosage-form patents (tablet core, coating, dissolution)
Multiple method-of-use patents (treatment of hypercholesterolemia, primary hyperlipidemia, mixed dyslipidemia, LDL-C target achievement)

The practical effect for competitors: Freedom-to-operate usually requires a claim-by-claim approach against Orange Book-listed patents (US) plus a national patent review in the main commercial markets.

When does exclusivity for ATC C10B combination products expire?

Short answer: Exclusivity timelines are a function of (1) earliest priority date for the active combination, (2) patent term adjustments (US), (3) supplementary protection certificates (EU), and (4) device of pediatric exclusivity or marketing exclusivity tied to the application pathway. For fixed-dose combinations, formulation patents and method-of-use patents often remain the limiting factor even after primary compound protection erodes.

What timelines matter most for generic or biosimilar-adjacent entry?

Earliest US patent expiration for the combination’s key composition claims
Orange Book expiration for each listed patent type:
- Drug substance
- Drug product (formulation)
- Method of use
Potential for “later-expiring” secondary patents:
- Dissolution profile patents
- Specific dose-strength claims
- Stability and storage conditions

Why C10B combination timelines often look uneven

C10B combinations frequently inherit different patent clocks for each API plus FDC-specific IP. This produces a situation where:

One component’s core compound patents approach expiry
The FDC formulation and regimen patents can still block generic “same-dose, same-form” entry
Litigation or settlement agreements can delay ANDA launches even when some patents expire

What is the Orange Book status of statin/ezetimibe and other C10B combinations?

Short answer: Orange Book listings usually include multiple patents per NDA, with a mixture of drug substance, drug product (formulation), and method-of-use patents. The “next launch” risk is driven by the patents that remain unexpired and those marked as requiring certification in Paragraph IV filings.

How to interpret Orange Book entries for C10B

Key fields to evaluate in Orange Book (US):

Patent expiration dates by patent number
Patent type: drug substance vs drug product vs method of use
Reference product mapping to fixed-dose strengths
Whether patents are systemically tied to a specific strength (important for “skinny” or strength-specific generic strategies)

What entries typically dominate Orange Book risk

Drug product patents: often the most persistent blockers because formulation claims remain valid longer than generic companies expect.
Method-of-use patents: can bar certain labeling claims even if composition protection ends, complicating Paragraph IV strategy.

Which generic entry risks exist for C10B lipid-modifying combinations?

Short answer: The primary risks are (1) adverse claim construction on method-of-use and formulation patents and (2) settlement-triggered delays. Generic launch timing hinges on whether an ANDA can avoid infringement or secure non-infringement/invalidity for each asserted claim.

Where Paragraph IV filings concentrate

Around drug product patents tied to FDC formulation
Around method-of-use patents involving LDL-C target achievement
Around specific combination strength compositions if FDC claims are strength-limited

Common “workarounds” that still hit IP

Changing excipient grades or coatings does not automatically avoid “drug product” infringement when claims cover generic dissolution and stability ranges
Reformulating to alter dissolution can still infringe if the claim recites “pharmacokinetic equivalence” or functional dissolution windows
Labeling carve-outs can be constrained by method-of-use patent scope

What patent litigation affects ATC Class C10B combinations?

Short answer: C10B litigation typically involves ANDA Paragraph IV suits that assert invalidity and non-infringement of combination formulation and method-of-use claims. Settlements frequently include delayed effective dates for generic launches and may include agreements not to market “at-risk” during a defined period.

What litigation patterns matter for market timing

Suit filing date relative to unexpired patent windows
Whether the case involves multiple asserted patents (drug substance, drug product, and method)
Whether the generics design around the formulation or only label around method-of-use claims

How settlements influence market dynamics

Settlements can:

Convert a potential at-risk launch into a delayed timeline
Narrow the generic labeling or omit certain strengths
Impose marketing carve-outs that shift the competitive landscape

How does ATC C10B compare across major therapeutic mechanisms (statin/ezetimibe vs other add-ons)?

Short answer: Statin/ezetimibe combinations tend to have dense oral formulation and method-of-use IP, creating a recurring pattern of delayed generic entry. Add-on mechanisms with newer modalities (biologics) shift risk from formulation into biologic product and manufacturing IP.

Comparison matrix: typical IP focus by mechanism

Mechanism cluster	Dominant delivery	Typical bottleneck IP	Competitive implication
Statin + ezetimibe FDC	Oral tablet	Drug product (FDC formulation) + method-of-use regimens	Generic launches often delayed by formulation and labeling restrictions
Statin + other oral add-on (non-ezetimibe)	Oral tablet/FDC or co-admin	Combination composition and dosage regimen	Design-arounds require claim-by-claim strategy
PCSK9 antibody add-ons	Injection (biologic)	Antibody sequence/epitope + manufacturing	Biosimilar timelines depend on biologic patent estates, not just FDA exclusivity

What formulations are protected by C10B combination patents?

Short answer: Drug product patents protect the physical and performance characteristics of fixed-dose tablets, including dissolution behavior, stability, and manufacturing parameters. Claims frequently target specific excipient systems, particle-size and coating structures, and release profiles.

Formulation subtopics that drive infringement risk

Dissolution profile claims: functional ranges aligned with in vivo performance
Stability/storage condition claims: moisture and thermal stability targets
Tablet composition windows: excipient amounts and ratios
Coating technology: film coat composition and thickness parameters
Strength-specific formulations: different strengths may map to different compositions and different IP

What method-of-use patents protect C10B combination regimens?

Short answer: Method-of-use patents commonly cover use in hypercholesterolemia populations and LDL-C reduction strategies. They often tie benefit to reaching predefined LDL-C goals or using titration sequences.

Method-of-use claim patterns

Treatment of primary hyperlipidemia/mixed dyslipidemia
Patient selection (high risk for cardiovascular events, statin-intolerant subgroups)
Dose initiation and escalation logic
Labeling-constrained efficacy outcomes

Why method-of-use patents matter even when composition expires

Even if a generic can avoid infringement of drug substance and drug product patents, it may still face liability if it markets under labeling that performs the patented method.

How strong is the patent estate for C10B combination drugs?

Short answer: The estate strength is usually highest for branded fixed-dose products with multiple Orange Book-listed patents across different categories. Strength is less about the number of patents in isolation and more about overlap of claim scope with the generic product’s intended formulation and labeling.

How to score patent estate strength for C10B

Use claim-level indicators:

Number of Orange Book patents still in force near the planned launch date
Mix of patent types (drug product and method-of-use elevate risk)
Whether patents are strength-specific or cover broad composition windows
Litigation history (asserted claims that survive motions suggest higher practical enforceability)

Which companies are challenging C10B combination exclusivity and where?

Short answer: Patent challenges in C10B usually come from large ANDA filers and generic leaders with established litigation capacity, with geographic focus on the US first due to Orange Book-driven Paragraph IV leverage.

Geographic competitive map

United States: Orange Book and ANDA-driven entry
European markets: patent term and SPC-driven exclusivity
UK and select APAC markets: typically follow local patent grant and enforcement timelines, with FDC formulation patents remaining key

What licensing deals shape ATC C10B combination availability?

Short answer: Licensing usually appears when:

A generic firm secures rights to manufacture or sell before full expiration (or to avoid specific infringements)
A branded company grants a co-promotion or distribution arrangement in exchange for delayed entry or design-around commitments

The net market dynamic is reduced “at-risk” competition and accelerated access via authorized supply.

Key patent and exclusivity checkpoints for C10B combinations (decision-ready)

Short answer: For launch planning, focus on three checkpoint layers.

1) Orange Book patent list checkpoints (US)

Identify all unexpired patents for the reference fixed-dose product
Prioritize drug product and method-of-use patents in risk ranking
Tie each patent to specific strengths where claims are strength-limited

2) Expiry calendar checkpoints

Earliest compound expiration
Latest FDC formulation expiration
Latest method-of-use expiration
Any pediatric or other market exclusivity offsets that shift practical launch dates

3) Litigation settlement checkpoints

Case status (trial, appeal)
Settlement effective dates
Carve-outs affecting specific strengths or labeling claims

Key Takeaways

C10B combination IP is driven by fixed-dose formulation patents and method-of-use regimen claims, not only primary compound protection.
Generic entry risk is highest when unexpired patents span multiple categories in the Orange Book, especially drug product plus method-of-use.
Market timing is commonly delayed by litigation and settlement structures even when some patent categories expire earlier.
Patent estate strength should be evaluated claim-by-claim against intended generic formulation and labeling, with strength-specific coverage treated as a major risk lever.
Comparative mechanism analysis shows oral statin/ezetimibe combinations typically have the most persistent formulation and regimen bottlenecks.

FAQs

How do C10B combination method-of-use claims affect generic labeling and switching strategies?
What claim types in C10B drug product patents most often survive invalidity challenges in ANDA litigation?
Do strength-specific fixed-dose claims in C10B combinations allow “partial” generic launches?
How do SPCs in Europe typically extend exclusivity for lipid-modifying combination products beyond US patent expiry?
What regulatory pathway choices (ANDA labeling carve-outs vs Paragraph IV strategies) best manage infringement risk in C10B combinations?

References (APA)

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
U.S. Food and Drug Administration. Drug Approval Reports and Drug Trials Snapshots (as applicable by product). https://www.fda.gov/drugs/drug-approvals-and-databases-drugs/drug-approvals-and-databases
European Medicines Agency. Supplementary Protection Certificates (SPC) and related guidance. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/supplementary-protection-certificates
OECD. Statutory framework and international notes on data exclusivity and patent term extensions (general background). https://www.oecd.org/health/biotechnology/

Drugs in ATC Class C10B

Subclasses in ATC: C10B - LIPID MODIFYING AGENTS, COMBINATIONS

Market Dynamics and Patent Landscape for ATC Class C10B (Lipid Modifying Agents, Combinations)